HALOZYME THERAPEUTICS, INC. (HALO)

PriceLoading quote

Financial charts

Revenue

Net income

Free cash flow

Total cash / debt

CashTotal debt

Financial statements

17 annual periodsNewest to oldest
20252024202320222021202020192018201720162015201420132012201120102009
Revenue$1.40B$1.02B$829.3M$660.1M$443.3M$267.6M$196.0M$151.9M$316.6M$146.7M$135.1M$75.3M$54.8M$42.3M$56.1M$13.6M$13.7M
Research & development$81.5M$79.0M$76.4M$66.6M$35.7M$34.2M$140.8M$150.3M$150.6M$150.8M$93.2M$79.7M$96.6M$70.0M$57.6M$51.8M$56.6M
Operating income$469.0M$551.5M$337.6M$267.5M$275.9M$144.3M−$67.6M−$69.3M$81.0M−$83.2M−$27.5M−$63.0M−$80.4M−$53.6M−$19.8M−$54.3M−$58.5M
EBITDAderived$480.4M$561.7M$348.7M$274.0M$278.9M$147.5M−$63.5M−$66.9M$83.2M−$80.8M−$25.8M−$61.3M−$79.2M−$52.5M−$18.7M−$52.7M−$57.0M
Net income$316.9M$444.1M$281.6M$202.1M$402.7M$129.1M−$72.2M−$80.3M$63.0M−$103.0M−$32.2M−$68.4M−$83.5M−$53.6M−$19.8M−$53.2M−$58.4M
Basic EPSper diluted share$2.64$3.50$2.13$1.48$2.86$0.95-$0.50-$0.56$0.46-$0.81-$0.25-$0.56-$0.74-$0.48-$0.19-$0.56-$0.67
Diluted EPSper diluted share$2.56$3.43$2.10$1.44$2.74$0.91-$0.50-$0.56$0.45-$0.81-$0.25-$0.56-$0.74-$0.48-$0.19-$0.56-$0.67

Insider buys & sells

Jul 1, 2024Jun 30, 2026
Buys0$0.00 disclosed value
Sells (SEC code S)154$62.79M disclosed value
154 recent transactions
TransactionInsiderTypeSharesPriceValueOwned after
Jun 29, 2026Form 4 · 10b5-1Krishnan MaheshDirectorSellCommon Stock7.3K$75.00$547.8K14.5K
Jun 3, 2026Form 4 · 10b5-1Torley HelenPRESIDENT AND CEOSellCommon Stock6.1K$69.69$425.1K767.8K
Jun 3, 2026Form 4 · 10b5-1Torley HelenPRESIDENT AND CEOSellCommon Stock2.0K$68.74$137.5K773.9K
Jun 3, 2026Form 4 · 10b5-1Torley HelenPRESIDENT AND CEOSellCommon Stock1.5K$67.68$101.5K775.9K
Jun 3, 2026Form 4 · 10b5-1Torley HelenPRESIDENT AND CEOSellCommon Stock400$66.37$26.5K777.4K